Enzyme replacement therapy: From concept to clinical practice

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 91, Issue 439, 2002, Pages 71-78

  Sly, W S ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Enzyme replacement therapy; Gaucher disease; Mucopolysaccharidosis type VII (MPS VII); glucuronidase

Indexed keywords

ADENOVIRUS VECTOR; BETA GLUCURONIDASE; COMPLEMENTARY DNA; GLUCOSYLCERAMIDASE; LENTIVIRUS VECTOR; MANNOSE RECEPTOR; RETROVIRUS VECTOR;

BIOACCUMULATION; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DISEASE MARKER; ENZYME ENGINEERING; ENZYME REPLACEMENT; GAUCHER DISEASE; GENETIC ENGINEERING; HUMAN; LYSOSOME; LYSOSOME STORAGE DISEASE; MACROMOLECULE; MUCOPOLYSACCHARIDOSIS TYPE 7; NONHUMAN; PRIORITY JOURNAL; VIRAL GENE THERAPY;

EID: 0036980794     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1651-2227.2002.tb03115.x     Document Type: Conference Paper

References (68)

1. de Duve C. Lysosomes, a new group of cytoplasmic particles. In: Hayashi T, editor. Subcellular particles. New York: Ronald Press, 1959: 128-59
2. de Duve C. Exploring cells with a centrifuge. Science 1975; 189: 186-94
3. de Duve C. From cytases to lysosomes. Fed Proc 1964; 23: 1045-9.
4. de Duve C. Lysosomes revisited. Eur J Biochem 1983; 137: 391-7
5. Hers HG. Alpha-glucosidase deficiency in generalized glycogen-storage disease (Pompe's disease). Biochem J 1963; 86: 11-16
6. Baudhuin P, Hers HG, Loeb H. An electron microscopic and biochemical study of type II glycogenosis. Lab Invest 1964; 13: 1139-52
7. Crawley AC, Brooks DA, Muller VJ, Petersen BA, Isaac EL, Bielicki J, et al. Enzyme replacement therapy in a feline model of Maroteaux-Lamy syndrome. J Clin Invest 1996; 97: 1864-73
8. Gonzalez-Noriega A, Grubb JH, Talkad V, Sly WS. Chloroquine inhibits lysosomal enzyme pinocytosis and enhances lysosomal enzyme secretion by impairing receptor recycling. J Cell Biol 1980; 85: 839-52
9. Kornfeld S. Structure and function of the mannose 6-phosphate/insulin-like growth factor II receptors. Annu Rev Biochem 1992; 61: 307-30
10. Kaback MM. Screening and prevention in Tay-Sachs disease: origins, update, and impact. Adv Genet 2001; 44: 253-65
11. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, Hill SC, et al. Replacement therapy for inherited enzyme deficiency-macrophage-targeted glucocerebrosidase for Gaucher's disease. N Engl J Med 1991; 324: 1464-70
12. Barranger JA, O'Rourke E. Lessons learned from the development of enzyme therapy for Gaucher disease. J Inherit Metab Dis 2001; 24(Suppl 2): 89-96
13. Eng CM, Guffon N, Wilcox WR, Germain DP, Lee P, Waldek S, et al. Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry's disease. N Engl J Med 2001; 345: 9-16
14. Schiffmann R, Kopp JB, Austin HA, III, Sabnis S, Moore DF, Weibel T, et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001; 285: 2743-9
15. Desnick RJ. Enzyme replacement and beyond. J Inherit Metab Dis 2001; 24: 251-65
16. Kakkis ED, Muenzer J, Tiller GE, Waber L, Belmont J, Passage M, et al. Enzyme-replacement therapy in mucopolysaccharidosis I. N Engl J Med 2001; 344: 182-8
17. Hall CW, Cantz M, Neufeld EF. Beta-glucuronidase deficiency mucopolysaccharidosis: studies in cultured fibroblasts. Arch Biochem Biophys 1973; 155: 32-8
18. Brot FE, Glaser JH, Roozen KJ, Sly WS, Stahl PD. In vitro correction of deficient human fibroblasts by beta-glucuronidase from different human sources. Biochem Biophys Res Commun 1974; 57: 1-8
19. Sly WS, Quinton BA, McAlister WH, Rimoin DL. Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 1973; 82: 249-57
20. Neufeld EF, Cantz MJ. Corrective factors for inborn errors of mucopolysaccharide metabolism. Ann N Y Acad Sci 1971; 179: 580-7
21. Barton RW, Neufeld EF. The Hurler corrective factor. Purification and some properties. J Biol Chem 1971; 246: 7773-9
22. Cantz M, Chrambach A, Bach G, Neufeld EF. The Hunter corrective factor. Purification and preliminary characterization. J Biol Chem 1972; 247: 5456-62
23. Kresse H, Neufeld EF. The Sanfilippo A corrective factor. Purification and mode of action. J Biol Chem 1972; 247: 2164-70
24. Crocker AC. Plasma infusion therapy for Hurler's syndrome. Pediatrics 1972; 50: 683-5
25. Erickson RP, Sandman R, Robertson WB, Epstein CJ. Inefficacy of fresh frozen plasma therapy of mucopolysaccharidosis II. Pediatrics 1972; 50: 693-701
26. Kaplan A, Achord DT, Sly WS. Phosphohexosyl components of a lysosomal enzyme are recognized by pinocytosis receptors on human fibroblasts. Proc Natl Acad Sci U S A 1977; 74: 2026-30
27. Natowicz MR, Chi MM, Lowry OH, Sly WS. Enzymatic identification of mannose 6-phosphate on the recognition marker for receptor-mediated pinocytosis of beta-glucuronidase by human fibroblasts. Proc Natl Acad Sci U S A 1979; 76: 4322-6
28. Kornfeld S, Reitman ML, Varki A, Goldberg D, Gabel CA. Steps in the phosphorylation of the high mannose oligosaccharides of lysosomal enzymes. Ciba Found Symp 1982; 92: 138-56
29. von Figura K, Hasilik A. Lysosomal enzymes and their receptors. Annu Rev Biochem 1986; 55: 167-93
30. Stahl PD, Rodman JS, Miller MJ, Schlesinger PH. Evidence for receptor-mediated binding of glycoproteins, glycoconjugates, and lysosomal glycosidases by alveolar macrophages. Proc Natl Acad Sci U S A 1978; 75: 1399-403
31. Achord D, Brot F, Gonzalez-Noriega A, Sly W, Stahl P. Human beta-glucuronidase. II. Fate of infused human placental beta-glucuronidase in the rat. Pediatr Res 1977; 11: 816-22
32. Achord DT, Brot FE, Bell CE, Sly WS. Human beta-glucuronidase: in vivo clearance and in vitro uptake by a glycoprotein recognition system on reticuloendothelial cells. Cell 1978; 15: 269-78
33. Brady RO, Pentchev PG, Gal AE, Hibbert SR, Dekaban AS. Replacement therapy for inherited enzyme deficiency. Use of purified glucocerebrosidase in Gaucher's disease. N Engl J Med 1974; 291: 989-93
34. Takasaki S, Murray GJ, Furbish FS, Brady RO, Barranger JA, Kobata A. Structure of the N-asparagine-linked oligosaccharide units of human placental beta-glucocerebrosidase. J Biol Chem 1984; 259: 10112-17
35. Murray GJ, Doebber TW, Shen TY, Wu MS, Ponpipom MM, Bugianesi RL, et al. Targeting of synthetically glycosylated human placental glucocerebrosidase. Biochem Med 1985; 34: 241-6
36. Barton NW, Furbish FS, Murray GJ, Garfield M, Brady RO. Therapeutic response to intravenous infusions of glucocerebrosidase in a patient with Gaucher disease. Proc Natl Acad Sci U S A 1990; 87: 1913-16
37. Pastores GM, Sibille AR, Grabowski GA. Enzyme therapy in Gaucher disease type I: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 1993; 82: 408-16
38. Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, Hermann G, Grabowski GA. Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatr Res 1992; 31: 496-502
39. Birkenmeier EH, Davisson MT, Beamer WG, Ganschow RE, Vogler CA, Gwynn B, et al. Murine mucopolysaccharidosis type VII. Characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest 1989; 83: 1258-6
40. Birkenmeier EH, Barker JE, Vogler CA, Kyle JW, Sly WS, Gwynn B, et al. Increased life span and correction of metabolic defects in murine mucopolysaccharidosis type VII after syngeneic bone marrow transplantation. Blood 1991; 78: 3081-92
41. Vogler C, Birkenmeier EH, Sly WS, Levy B, Pegors C, Kyle JW, et al. A murine model of mucopolysaccharidosis VII. Gross and microscopic findings in beta-glucuronidase-deficient mice. Am J Pathol 1990; 136: 207-17
42. Ohlemiller KK, Vogler CA, Roberts M, Galvin N, Sands MS. Retinal function is improved in a murine model of a lysosomal storage disease following bone marrow transplantation. Exp Eye Res 2000; 71: 469-81
43. Sands MS, Erway LC, Vogler C, Sly WS, Birkenmeier EH. Syngeneic bone marrow transplantation reduces the hearing loss associated with murine mucopolysaccharidosis type VII. Blood 1995; 86: 2033-40
44. Sands MS, Barker JE, Vogler C, Levy B, Gwynn B, Galvin N, et al. Treatment of murine mucopolysaccharidosis type VII by syngeneic bone marrow transplantation in neonates. Lab Invest 1993; 68: 676-86
45. Soper BW, Lessard MD, Vogler CA, Levy B, Beamer WG, Sly WS, et al. Nonablative neonatal marrow transplantation attenuates functional and physical defects of beta-glucuronidase deficiency. Blood 2001; 97: 1498-504
46. Snyder EY, Taylor RM, Wolfe JH. Neural progenitor cell engraftment corrects lysosomal storage throughout the MPS VII mouse brain. Nature 1995; 374: 367-70
47. Daly TM, Lorenz RG, Sands MS. Abnormal immune function in vivo in a murine model of lysosomal storage disease. Pediatr Res 2000; 47: 757-62
48. O'Connor LH, Erway LC, Vogler CA, Sly WS, Nicholes A, Grubb J, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function. J Clin Invest 1998; 101: 1394-400
49. Soper BW, Pung AW, Vogler CA, Grubb JH, Sly WS, Barker JE. Enzyme replacement therapy improves reproductive performance in mucopolysaccharidosis type VII mice but does not prevent postnatal losses. Pediatr Res 1999; 45: 180-6
50. Vogler C, Sands M, Higgins A, Levy B, Grubb J, Birkenmeier EH, et al. Enzyme replacement with recombinant beta-glucuronidase in the newborn mucopolysaccharidosis type VII mouse. Pediatr Res 1993; 34: 837-40
51. Sands MS, Vogler C, Kyle JW, Grubb JH, Levy B, Galvin N, et al. Enzyme replacement therapy for murine mucopolysaccharidosis type VII. J Clin Invest 1994; 93: 2324-31
52. Sands MS, Vogler C, Torrey A, Levy B, Gwynn B, Grubb J, et al. Murine mucopolysaccharidosis type VII: long term therapeutic effects of enzyme replacement and enzyme replacement followed by bone marrow transplantation. J Clin Invest 1997; 99: 1596-605
53. Sands MS, Vogler CA, Ohlemiller KK, Roberts MS, Grubb JH, Levy B, et al. Biodistribution, kinetics, and efficacy of highly phosphorylated and non-phosphorylated beta-glucuronidase in the murine model of mucopolysaccharidosis VII. J Biol Chem 2001; 276: 43160-5
54. Brooks AI, Stein CS, Hughes SM, Heth J, McCray PM, Jr, Sauter SL, et al. Functional correction of established central nervous system deficits in an animal model of lysosomal storage disease with feline immunodeficiency virus-based vectors. Proc Natl Acad Sci U S A 2002; 99: 6216-21
55. Zhu J, Kang W, Wolfe JH, Fraser NW. Significantly increased expression of beta-glucuronidase in the central nervous system of mucopolysaccharidosis type VII mice from the latency-associated transcript promoter in a nonpathogenic herpes simplex virus type 1 vector. Mol Ther 2000; 2: 82-94
56. Bosch A, Perret E, Desmaris N, Trono D, Heard JM. Reversal of pathology in the entire brain of mucopolysaccharidosis type VII mice after lentivirus-mediated gene transfer. Hum Gene Ther 2000; 11: 1139-50
57. Vogler C, Barker J, Sands MS, Levy B, Galvin N, Sly WS. Murine mucopolysaccharidosis VIL: impact of therapies on the phenotype, clinical course, and pathology in a model of a lysosomal storage disease. Pediatr Dev Pathol 2001; 4: 421-33
58. Daly TM, Vogler C, Levy B, Haskins ME, Sands MS. Neonatal gene transfer leads to widespread correction of pathology in a murine model of lysosomal storage disease. Proc Natl Acad Sci U S A 1999; 96: 2296-300
59. Daly TM, Ohlemiller KK, Roberts MS, Vogler CA, Sands MS. Prevention of systemic clinical disease in MPS VII mice following AAV-mediated neonatal gene transfer. Gene Ther 2001; 8: 1291-8
60. Skorupa AF, Fisher KJ, Wilson JM, Parente MK, Wolfe JH. Sustained production of beta-glucuronidase from localized sites after AAV vector gene transfer results in widespread distribution of enzyme and reversal of lysosomal storage lesions in a large volume of brain in mucopolysaccharidosis VII mice. Exp Neurol 1999; 160: 17-27
61. Bosch A, Perret E, Desmaris N, Heard JM. Long-term and significant correction of brain lesions in adult mucopolysaccharidosis type VII mice using recombinant AAV vectors. Mol Ther 2000; 1: 63-70
62. Elliger SS, Elliger CA, Aguilar CP, Raju NR, Watson GL. Elimination of lysosomal storage in brains of MPS VII mice treated by intrathecal administration of an adeno-associated virus vector. Gene Ther 1999; 6: 1175-8
63. Sferra TJ, Qu G, McNeely D, Rennard R, Clark KR, Lo WD, et al. Recombinant adeno-associated virus-mediated correction of lysosomal storage within the central nervous system of the adult mucopolysaccharidosis type VII mouse. Hum Gene Ther 2000; 11: 507-19
64. Frisella WA, O'Connor LH, Vogler CA, Roberts M, Walkley S, Levy B, et al. Intracranial injection of recombinant adeno-associated virus improves cognitive function in a murine model of mucopolysaccharidosis type VII. Mol Ther 2001; 3: 351-8
65. Ghodsi A, Stein C, Derksen T, Martins I, Anderson RD, Davidson BL. Systemic hyperosmolality improves beta-glucuronidase distribution and pathology in murine MPS VII brain following intraventricular gene transfer. Exp Neurol 1999; 160: 109-16
66. Ohashi T, Watabe K, Uehara K, Sly WS, Vogler C, Eto Y. Adenovirus-mediated gene transfer and expression of human beta-glucuronidase gene in the liver, spleen, and central nervous system in mucopolysaccharidosis type VII mice. Proc Natl Acad Sci U S A 1997; 94: 1287-92
67. Watson GL, Sayles JN, Chen C, Elliger SS, Elliger CA, Raju NR, et al. Treatment of lysosomal storage disease in MPS VII mice using a recombinant adeno-associated virus. Gene Ther 1998; 5: 1642-9
68. Xia H, Mao Q, Davidson BL. The HIV Tat protein transduction domain improves the biodistribution of beta-glucuronidase expressed from recombinant viral vectors. Nat Biotechnol 2001; 19: 640-4